News by topic

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

New and experimental hepatitis C treatment news

Show

From To
New and experimental hepatitis C treatment
Hepatitis C drug goes after patients’ RNA

The new drug, called miravirsen, binds to microRNA-122, sequesters it and indirectly thwarts viral replication, says study coauthor Harry Janssen, a hepatologist and physician at the University of Toronto. Janssen and colleagues report the findings March 27 in the New England Journal of Medicine.

Published
28 March 2013
From
Science News
New and experimental hepatitis C treatment
'Sponge' Drug Shows Promise For Treating Hepatitis C

One of the drugs in the pipeline, called miravirsen, may be able to stop the virus with little side effects, doctors from University Health Network in Toronto, Canada, reported Wednesday.

Published
28 March 2013
From
NPR (blog)
New and experimental hepatitis C treatment
Gilead Announces Update on Phase 3 Study of Oral Fixed-Dose Combination of Sofosbuvir and Ledipasvir for Genotype 1 Hepatitis C Patients

A planned review by the study's Data and Safety Monitoring Board (DSMB) of safety data from 200 patients in all four arms and of SVR4 rates (sustained virologic response four weeks after completion of therapy) from 100 patients in the two 12-week duration arms concluded that the trial should continue without modification.

Published
26 March 2013
From
Gilead press release
New and experimental hepatitis C treatment
Sofosbuvir plus ribavirin works well for hard-to-treat inner-city hepatitis C patients

A simple 24-week oral regimen consisting of sofosbuvir plus full-dose ribavirin cured nearly 70% of previously untreated people with genotype 1 hepatitis C, many of whom had

Published
20 March 2013
By
Liz Highleyman
New and experimental hepatitis C treatment
AbbVie interferon-free combinations cure most newly treated hepatitis C patients

All-oral regimens consisting of the HCV protease inhibitor ABT-450, a non-nucleoside polymerase inhibitor and ribavirin led to sustained response for more than 90% of previously untreated hepatitis 

Published
20 March 2013
By
Liz Highleyman
New and experimental hepatitis C treatment
Presidio Pharmaceuticals Announces Collaboration with Boehringer Ingelheim

The Parties to Initiate a Phase IIa Trial of an All-Oral Combination of Presidio’s HCV NS5A inhibitor (PPI-668) with Faldaprevir (BI201335) and BI207127 for the Treatment of Patients with Hepatitis C.

Published
13 March 2013
From
Presidio press release
New and experimental hepatitis C treatment
Adding telaprevir improves acute hepatitis C treatment for HIV-positive men

Adding telaprevir (Incivo or Incivek) to pegylated interferon and ribavirin shortens the duration of treatment and increases the likelihood of a cure for HIV-positive men with acute

Published
12 March 2013
By
Liz Highleyman
New and experimental hepatitis C treatment
Simeprevir & sofosbuvir demonstrates good early cure rate with or without ribavirin

An all-oral combination of simeprevir plus sofosbuvir, with or without ribavirin, led to an early cure for most hard-to-treat prior null responders with genotype 1 hepatitis C

Published
12 March 2013
By
Liz Highleyman
New and experimental hepatitis C treatment
Faldaprevir ups interferon response in HIV/HCV co-infection

Adding the hepatitis C virus (HCV) protease inhibitor faldaprevir (formerly BI 201335) to pegylated interferon and ribavirin led to a higher early response rate and the potential

Published
11 March 2013
By
Liz Highleyman
New and experimental hepatitis C treatment
Simeprevir pushes HCV cure rate above 75% for HIV/HCV co-infection

Adding the new hepatitis C virus (HCV) protease inhibitor simeprevir (formerly TMC435) to pegylated interferon and ribavirin cures about three-quarters of HIV/HCV co-infected people, most of them with

Published
11 March 2013
By
Liz Highleyman
← Prev1...23456...32Next →

Filter by country